Venous Thromboembolic Disease

Restricted access

Venous thromboembolism (VTE) remains a common and life-threatening complication among patients with cancer. Thromboprophylaxis can be used to prevent the occurrence of VTE in patients with cancer who are considered at high risk for developing this complication. Therefore, it is critical to recognize the various risk factors for VTE in patients with cancer. Risk assessment tools are available to help identify patients for whom discussions regarding the potential benefits and risks of thromboprophylaxis would be appropriate. The NCCN Clinical Practice Guidelines in Oncology for VTE provide recommendations on risk evaluation, diagnosis, prevention, and treatment of VTE in patients with cancer.

  • 1.

    Khorana AA, Francis CW, Culakova E. Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol 2006;24:484490.

  • 2.

    Sallah S, Wan JY, Nguyen NP. Venous thrombosis in patients with solid tumors: determination of frequency and characteristics. Thromb Haemost 2002;87:575579.

    • Search Google Scholar
    • Export Citation
  • 3.

    Khorana AA, Dalal M, Lin J, Connolly GC. Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States. Cancer 2013;119:648655.

    • Search Google Scholar
    • Export Citation
  • 4.

    Heit JA, O’Fallon WM, Petterson TM. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med 2002;162:12451248.

    • Search Google Scholar
    • Export Citation
  • 5.

    Monreal M, Fernandez-Llamazares J, Perandreu J. Occult cancer in patients with venous thromboembolism: which patients, which cancers. Thromb Haemost 1997;78:13161318.

    • Search Google Scholar
    • Export Citation
  • 6.

    Bick RL. Cancer-associated thrombosis: focus on extended therapy with dalteparin. J Support Oncol 2006;4:115120.

  • 7.

    Lopez JA, Kearon C, Lee AY. Deep venous thrombosis. Hematology Am Soc Hematol Educ Program 2004:439456.

  • 8.

    Prandoni P, Piccioli A, Girolami A. Cancer and venous thromboembolism: an overview. Haematologica 1999;84:437445.

  • 9.

    Otten HM, Mathijssen J, ten Cate H. Symptomatic venous thromboembolism in cancer patients treated with chemotherapy: an underestimated phenomenon. Arch Intern Med 2004;164:190194.

    • Search Google Scholar
    • Export Citation
  • 10.

    Chew HK, Wun T, Harvey D. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 2006;166:458464.

    • Search Google Scholar
    • Export Citation
  • 11.

    Chew HK, Wun T, Harvey DJ. Incidence of venous thromboembolism and the impact on survival in breast cancer patients. J Clin Oncol 2007;25:7076.

    • Search Google Scholar
    • Export Citation
  • 12.

    Kuderer NM, Francis CW, Culakova E. Venous thromboembolism and all-cause mortality in cancer patients receiving chemotherapy [abstract]. J Clin Oncol 2008;26(Suppl 15):Abstract 9521.

    • Search Google Scholar
    • Export Citation
  • 13.

    Martino MA, Williamson E, Siegfried S. Diagnosing pulmonary embolism: experience with spiral CT pulmonary angiography in gynecologic oncology. Gynecol Oncol 2005;98:289293.

    • Search Google Scholar
    • Export Citation
  • 14.

    Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000;343:18461850.

  • 15.

    Agnelli G, Bolis G, Capussotti L. A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project. Ann Surg 2006;243:8995.

    • Search Google Scholar
    • Export Citation
  • 16.

    Cohen AT, Alikhan R, Arcelus JI. Assessment of venous thromboembolism risk and the benefits of thromboprophylaxis in medical patients. Thromb Haemost 2005;94:750759.

    • Search Google Scholar
    • Export Citation
  • 17.

    Khorana AA, Connolly GC. Assessing risk of venous thromboembolism in the patient with cancer. J Clin Oncol 2009;27:48394847.

  • 18.

    Connolly GC, Khorana AA. Emerging risk stratification approaches to cancer-associated thrombosis: risk factors, biomarkers and a risk score. Thromb Res 2010;125(Suppl 2):17.

    • Search Google Scholar
    • Export Citation
  • 19.

    Centers for Disease Control and Prevention (CDC). Venous thromboembolism in adult hospitalizations—United States, 2007-2009. MMWR Morb Mortal Wkly Rep 2012;61:401404.

    • Search Google Scholar
    • Export Citation
  • 20.

    Ageno W, Squizzato A, Garcia D, Imberti D. Epidemiology and risk factors of venous thromboembolism. Semin Thromb Hemost 2006;32:651658.

  • 21.

    Hicks LK, Cheung MC, Ding K. Venous thromboembolism and nonsmall cell lung cancer: a pooled analysis of National Cancer Institute of Canada Clinical Trials Group trials. Cancer 2009;115:55165525.

    • Search Google Scholar
    • Export Citation
  • 22.

    Khorana AA, Kuderer NM, Culakova E. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008;111:49024907.

    • Search Google Scholar
    • Export Citation
  • 23.

    Khorana AA, Francis CW, Culakova E, Lyman GH. Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer 2005;104:28222829.

    • Search Google Scholar
    • Export Citation
  • 24.

    Mandalà M, Barni S, Prins M. Acquired and inherited risk factors for developing venous thromboembolism in cancer patients receiving adjuvant chemotherapy: a prospective trial. Ann Oncol 2010;21:871876.

    • Search Google Scholar
    • Export Citation
  • 25.

    Darze ES, Latado AL, Guimaraes AG. Incidence and clinical predictors of pulmonary embolism in severe heart failure patients admitted to a coronary care unit. Chest 2005;128:25762580.

    • Search Google Scholar
    • Export Citation
  • 26.

    Kroger K, Weiland D, Ose C. Risk factors for venous thromboembolic events in cancer patients. Ann Oncol 2006;17:297303.

  • 27.

    Prandoni P, Lensing AW, Prins MH. Residual venous thrombosis as a predictive factor of recurrent venous thromboembolism. Ann Intern Med 2002;137:955960.

    • Search Google Scholar
    • Export Citation
  • 28.

    Prandoni P, Lensing AW, Piccioli A. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002;100:34843488.

    • Search Google Scholar
    • Export Citation
  • 29.

    Rogers MA, Levine DA, Blumberg N. Triggers of hospitalization for venous thromboembolism. Circulation 2012;125:20922099.

  • 30.

    Schmidt M, Horvath-Puho E, Thomsen RW. Acute infections and venous thromboembolism. J Intern Med 2012;271:608618.

  • 31.

    Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005;293:715722.

  • 32.

    Heit JA, Silverstein MD, Mohr DN. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 2000;160:809815.

    • Search Google Scholar
    • Export Citation
  • 33.

    Ogren M, Bergqvist D, Wahlander K. Trousseau’s syndrome: what is the evidence? A population-based autopsy study. Thromb Haemost 2006;95:541545.

    • Search Google Scholar
    • Export Citation
  • 34.

    Hall IE, Andersen MS, Krumholz HM, Gross CP. Predictors of venous thromboembolism in patients with advanced common solid cancers. J Cancer Epidemiol 2009;2009:182521182521.

    • Search Google Scholar
    • Export Citation
  • 35.

    Sandhu R, Pan CX, Wun T. The incidence of venous thromboembolism and its effect on survival among patients with primary bladder cancer. Cancer 2010;116:25962603.

    • Search Google Scholar
    • Export Citation
  • 36.

    Levitan N, Dowlati A, Remick SC. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore) 1999;78:285291.

    • Search Google Scholar
    • Export Citation
  • 37.

    Gerber DE, Grossman SA, Streiff MB. Management of venous thromboembolism in patients with primary and metastatic brain tumors. J Clin Oncol 2006;24:13101318.

    • Search Google Scholar
    • Export Citation
  • 38.

    Lee AY, Levine MN. Venous thromboembolism and cancer: risks and outcomes. Circulation 2003;107:I1721.

  • 39.

    Marras LC, Geerts WH, Perry JR. The risk of venous thromboembolism is increased throughout the course of malignant glioma: an evidence-based review. Cancer 2000;89:640646.

    • Search Google Scholar
    • Export Citation
  • 40.

    Connolly GC, Dalal M, Lin J, Khorana AA. Incidence and predictors of venous thromboembolism (VTE) among ambulatory patients with lung cancer. Lung Cancer 2012;78:253258.

    • Search Google Scholar
    • Export Citation
  • 41.

    Falanga A, Marchetti M. Venous thromboembolism in the hematologic malignancies. J Clin Oncol 2009;27:48484857.

  • 42.

    Palumbo A, Rajkumar SV, Dimopoulos MA. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 2008;22:414423.

    • Search Google Scholar
    • Export Citation
  • 43.

    Ottinger H, Belka C, Kozole G. Deep venous thrombosis and pulmonary artery embolism in high-grade non Hodgkin’s lymphoma: incidence, causes and prognostic relevance. Eur J Haematol 1995;54:186194.

    • Search Google Scholar
    • Export Citation
  • 44.

    Andtbacka RH, Babiera G, Singletary SE. Incidence and prevention of venous thromboembolism in patients undergoing breast cancer surgery and treated according to clinical pathways. Ann Surg 2006;243:96101.

    • Search Google Scholar
    • Export Citation
  • 45.

    Haddad TC, Greeno EW. Chemotherapy-induced thrombosis. Thromb Res 2006;118:555568.

  • 46.

    Ay C, Dunkler D, Marosi C. Prediction of venous thromboembolism in cancer patients. Blood 2010;116:53775382.

  • 47.

    Cummings SR, Eckert S, Krueger KA. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 1999;281:21892197.

    • Search Google Scholar
    • Export Citation
  • 48.

    Decensi A, Maisonneuve P, Rotmensz N. Effect of tamoxifen on venous thromboembolic events in a breast cancer prevention trial. Circulation 2005;111:650656.

    • Search Google Scholar
    • Export Citation
  • 49.

    Fisher B, Costantino JP, Wickerham DL. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 2005;97:16521662.

    • Search Google Scholar
    • Export Citation
  • 50.

    Fisher B, Costantino JP, Wickerham DL. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:13711388.

    • Search Google Scholar
    • Export Citation
  • 51.

    Vogel VG, Costantino JP, Wickerham DL. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: preventing breast cancer. Cancer Prev Res (Phila) 2010;3:696706.

    • Search Google Scholar
    • Export Citation
  • 52.

    Anderson GL, Limacher M, Assaf AR. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA 2004;291:17011712.

    • Search Google Scholar
    • Export Citation
  • 53.

    Rossouw JE, Anderson GL, Prentice RL. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA 2002;288:321333.

    • Search Google Scholar
    • Export Citation
  • 54.

    Blanco-Molina A, Trujillo-Santos J, Tirado R. Venous thromboembolism in women using hormonal contraceptives. Findings from the RIETE Registry. Thromb Haemost 2009;101:478482.

    • Search Google Scholar
    • Export Citation
  • 55.

    Gomes MP, Deitcher SR. Risk of venous thromboembolic disease associated with hormonal contraceptives and hormone replacement therapy: a clinical review. Arch Intern Med 2004;164:19651976.

    • Search Google Scholar
    • Export Citation
  • 56.

    Lidegaard O, Nielsen LH, Skovlund CW. Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9. BMJ 2011;343:d6423.

    • Search Google Scholar
    • Export Citation
  • 57.

    Manzoli L, De Vito C, Marzuillo C. Oral contraceptives and venous thromboembolism: a systematic review and meta-analysis. Drug Saf 2012;35:191205.

    • Search Google Scholar
    • Export Citation
  • 58.

    Jick SS, Hernandez RK. Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case-control study using United States claims data. BMJ 2011;342:d2151.

    • Search Google Scholar
    • Export Citation
  • 59.

    Parkin L, Sharples K, Hernandez RK, Jick SS. Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested case-control study based on UK General Practice Research Database. BMJ 2011;342:d2139.

    • Search Google Scholar
    • Export Citation
  • 60.

    Leaf AN, Propert K, Corcoran C. Phase III study of combined chemohormonal therapy in metastatic prostate cancer (ECOG 3882): an Eastern Cooperative Oncology Group study. Med Oncol 2003;20:137146.

    • Search Google Scholar
    • Export Citation
  • 61.

    Bennett CL, Angelotta C, Yarnold PR. Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer. JAMA 2006;296:25582560.

    • Search Google Scholar
    • Export Citation
  • 62.

    El Accaoui RN, Shamseddeen WA, Taher AT. Thalidomide and thrombosis. A meta-analysis. Thromb Haemost 2007;97:10311036.

  • 63.

    Hussein MA. Thromboembolism risk reduction in multiple myeloma patients treated with immunomodulatory drug combinations. Thromb Haemost 2006;95:924930.

    • Search Google Scholar
    • Export Citation
  • 64.

    Knight R, DeLap RJ, Zeldis JB. Lenalidomide and venous thrombosis in multiple myeloma. N Engl J Med 2006;354:20792080.

  • 65.

    Weber DM, Chen C, Niesvizky R. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007;357:21332142.

    • Search Google Scholar
    • Export Citation
  • 66.

    Zangari M, Siegel E, Barlogie B. Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. Blood 2002;100:11681171.

    • Search Google Scholar
    • Export Citation
  • 67.

    Bennett CL, Silver SM, Djulbegovic B. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 2008;299:914924.

    • Search Google Scholar
    • Export Citation
  • 68.

    Baarslag HJ, Koopman MM, Hutten BA. Long-term follow-up of patients with suspected deep vein thrombosis of the upper extremity: survival, risk factors and post-thrombotic syndrome. Eur J Intern Med 2004;15:503507.

    • Search Google Scholar
    • Export Citation
  • 69.

    Prandoni P, Polistena P, Bernardi E. Upper-extremity deep vein thrombosis. Risk factors, diagnosis, and complications. Arch Intern Med 1997;157:5762.

    • Search Google Scholar
    • Export Citation
  • 70.

    Verso M, Agnelli G. Venous thromboembolism associated with long-term use of central venous catheters in cancer patients. J Clin Oncol 2003;21:36653675.

    • Search Google Scholar
    • Export Citation
  • 71.

    Lee AY, Levine MN, Butler G. Incidence, risk factors, and outcomes of catheter-related thrombosis in adult patients with cancer. J Clin Oncol 2006;24:14041408.

    • Search Google Scholar
    • Export Citation
  • 72.

    Joffe HV, Goldhaber SZ. Upper-extremity deep vein thrombosis. Circulation 2002;106:18741880.

  • 73.

    Linenberger ML. Catheter-related thrombosis: risks, diagnosis, and management. J Natl Compr Canc Netw 2006;4:889901.

  • 74.

    van Rooden CJ, Schippers EF, Barge RM. Infectious complications of central venous catheters increase the risk of catheter-related thrombosis in hematology patients: a prospective study. J Clin Oncol 2005;23:26552660.

    • Search Google Scholar
    • Export Citation
  • 75.

    Garcia DA, Baglin TP, Weitz JI, Samama MM. Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141:e24S43S.

    • Search Google Scholar
    • Export Citation
  • 76.

    Kahn SR, Lim W, Dunn AS. Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141:e195S226S.

    • Search Google Scholar
    • Export Citation
  • 77.

    Kearon C, Akl EA, Comerota AJ. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141:e419S494S.

    • Search Google Scholar
    • Export Citation
  • 78.

    Wells PS, Anderson DR, Rodger MA. A randomized trial comparing 2 low-molecular-weight heparins for the outpatient treatment of deep vein thrombosis and pulmonary embolism. Arch Intern Med 2005;165:733738.

    • Search Google Scholar
    • Export Citation
  • 79.

    sanofi-aventis US, LLC. Prescribing information: Lovenox (enoxaparin sodium injection). 2009. Available at: http://products.sanofi-aventis.us/lovenox/lovenox.html. Accessed February 1, 2011.

    • Search Google Scholar
    • Export Citation
  • 80.

    LEO Pharmaceutical Products. Prescribing information: Innohep (tinzaparin sodium injection) for subcutaneous (SC) use only. 2008. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020484s011lbl.pdf. Accessed February 18, 2011.

    • Search Google Scholar
    • Export Citation
  • 81.

    Eisai, Inc; Pfizer, Inc. Prescribing information: FRAGMIN (dalteparin sodium injection) for subcutaneous use only. 2010. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020287s050lbl.pdf. Accessed March 11, 2011.

    • Search Google Scholar
    • Export Citation
  • 82.

    Cheer SM, Dunn CJ, Foster R. Tinzaparin sodium: a review of its pharmacology and clinical use in the prophylaxis and treatment of thromboembolic disease. Drugs 2004;64:14791502.

    • Search Google Scholar
    • Export Citation
  • 83.

    Lee AY, Levine MN, Baker RI. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003;349:146153.

    • Search Google Scholar
    • Export Citation
  • 84.

    Neely JL, Carlson SS, Lenhart SE. Tinzaparin sodium: a low-molecular-weight heparin. Am J Health Syst Pharm 2002;59:14261436.

  • 85.

    Nutescu EA, Shapiro NL, Feinstein H, Rivers CW. Tinzaparin: considerations for use in clinical practice. Ann Pharmacother 2003;37:18311840.

  • 86.

    Planes A, Samama MM, Lensing AW. Prevention of deep vein thrombosis after hip replacement—comparison between two low-molecular heparins, tinzaparin and enoxaparin. Thromb Haemost 1999;81:2225.

    • Search Google Scholar
    • Export Citation
  • 87.

    Mandalà M, Falanga A, Roila F. Management of venous thromboembolism in cancer patients: ESMO clinical recommendations. Ann Oncol 2008;19(Suppl 2):126127.

    • Search Google Scholar
    • Export Citation
  • 88.

    Cook LM, Kahn SR, Goodwin J, Kovacs MJ. Frequency of renal impairment, advanced age, obesity and cancer in venous thromboembolism patients in clinical practice. J Thromb Haemost 2007;5:937941.

    • Search Google Scholar
    • Export Citation
  • 89.

    Hirsh J, Bauer KA, Donati MB. Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133:141S159S.

    • Search Google Scholar
    • Export Citation
  • 90.

    Michota F, Merli G. Anticoagulation in special patient populations: are special dosing considerations required? Cleve Clin J Med 2005;72(Suppl 1):S3742.

    • Search Google Scholar
    • Export Citation
  • 91.

    Sanderink GJ, Guimart CG, Ozoux ML. Pharmacokinetics and pharmacodynamics of the prophylactic dose of enoxaparin once daily over 4 days in patients with renal impairment. Thromb Res 2002;105:225231.

    • Search Google Scholar
    • Export Citation
  • 92.

    Lim W, Dentali F, Eikelboom JW, Crowther MA. Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med 2006;144:673684.

    • Search Google Scholar
    • Export Citation
  • 93.

    Hulot JS, Montalescot G, Lechat P. Dosing strategy in patients with renal failure receiving enoxaparin for the treatment of non-ST-segment elevation acute coronary syndrome. Clin Pharmacol Ther 2005;77:542552.

    • Search Google Scholar
    • Export Citation
  • 94.

    Kruse MW, Lee JJ. Retrospective evaluation of a pharmacokinetic program for adjusting enoxaparin in renal impairment. Am Heart J 2004;148:582589.

    • Search Google Scholar
    • Export Citation
  • 95.

    Shprecher AR, Cheng-Lai A, Madsen EM. Peak antifactor xa activity produced by dalteparin treatment in patients with renal impairment compared with controls. Pharmacotherapy 2005;25:817822.

    • Search Google Scholar
    • Export Citation
  • 96.

    Douketis J, Cook D, Meade M. Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin: an assessment of safety and pharmacodynamics: the DIRECT study. Arch Intern Med 2008;168:18051812.

    • Search Google Scholar
    • Export Citation
  • 97.

    Mahe I, Aghassarian M, Drouet L. Tinzaparin and enoxaparin given at prophylactic dose for eight days in medical elderly patients with impaired renal function: a comparative pharmacokinetic study. Thromb Haemost 2007;97:581586.

    • Search Google Scholar
    • Export Citation
  • 98.

    Pautas E, Gouin I, Bellot O. Safety profile of tinzaparin administered once daily at a standard curative dose in two hundred very elderly patients. Drug Saf 2002;25:725733.

    • Search Google Scholar
    • Export Citation
  • 99.

    Siguret V, Pautas E, Fevrier M. Elderly patients treated with tinzaparin (Innohep) administered once daily (175 anti-Xa IU/kg): anti-Xa and anti-IIa activities over 10 days. Thromb Haemost 2000;84:800804.

    • Search Google Scholar
    • Export Citation
  • 100.

    Leizorovicz A. Tinzaparin Compared to Unfractionated Heparin for Initial Treatment of Deep Vein Thrombosis in Very Elderly Patients with Renal Insufficiency-the IRIS Trial [abstract]. Blood 2008;112:Abstract 434.

    • Search Google Scholar
    • Export Citation
  • 101.

    Kucher N, Leizorovicz A, Vaitkus PT. Efficacy and safety of fixed low-dose dalteparin in preventing venous thromboembolism among obese or elderly hospitalized patients: a subgroup analysis of the PREVENT trial. Arch Intern Med 2005;165:341345.

    • Search Google Scholar
    • Export Citation
  • 102.

    GlaxoSmithKline. Prescribing information: ARIXTRA (fondaparinux sodium) solution for subcutaneous injection. 2011. Available at: http://us.gsk.com/products/assets/us_arixtra.pdf. Accessed May 11, 2012.

    • Search Google Scholar
    • Export Citation
  • 103.

    Prandoni P. How I treat venous thromboembolism in patients with cancer. Blood 2005;106:40274033.

  • 104.

    Savi P, Chong BH, Greinacher A. Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies: a blinded comparative multicenter study with unfractionated heparin. Blood 2005;105:139144.

    • Search Google Scholar
    • Export Citation
  • 105.

    Warkentin TE, Greinacher A, Koster A, Lincoff AM. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 2008;133:340S380S.

    • Search Google Scholar
    • Export Citation
  • 106.

    Cohen AT, Davidson BL, Gallus AS. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ 2006;332:325329.

    • Search Google Scholar
    • Export Citation
  • 107.

    Janssen Pharmaceuticals, Inc. Prescribing Information: XARELTO (rivaroxaban) tablets. 2011. Available at: http://www.xareltohcp.com/sites/default/files/pdf/xarelto_0.pdf#zoom=100. Accessed May 11, 2012.

    • Search Google Scholar
    • Export Citation
  • 108.

    Cohen AT, Spiro TE, Buller HR. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med 2013;368:513523.

  • 109.

    Buller HR, Prins MH, Lensin AW. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012;366:12871297.

  • 110.

    Bristol-Myers Squibb Company. Prescribing Information: ELIQUIS (apixaban) tablets for oral use. 2012. Available at: http://packageinserts.bms.com/pi/pi_eliquis.pdf. Accessed March 11, 2013.

    • Search Google Scholar
    • Export Citation
  • 111.

    Goldhaber SZ, Leizorovicz A, Kakkar AK. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med 2011;365:21672177.

    • Search Google Scholar
    • Export Citation
  • 112.

    Agnelli G, Buller HR, Cohen A. Apixaban for extended treatment of venous thromboembolism. N Engl J Med 2013;368:699708.

  • 113.

    Agnelli G, Buller HR, Cohen A. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013;369:513523.

  • 114.

    Hirsh J, Anand SS, Halperin JL, Fuster V. Mechanism of action and pharmacology of unfractionated heparin. Arterioscler Thromb Vasc Biol 2001;21:10941096.

    • Search Google Scholar
    • Export Citation
  • 115.

    Clagett GP, Reisch JS. Prevention of venous thromboembolism in general surgical patients. Results of meta-analysis. Ann Surg 1988;208:227240.

    • Search Google Scholar
    • Export Citation
  • 116.

    Geerts WH, Bergqvist D, Pineo GF. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 2008;133:453.

    • Search Google Scholar
    • Export Citation
  • 117.

    King CS, Holley AB, Jackson JL. Twice vs three times daily heparin dosing for thromboembolism prophylaxis in the general medical population: a metaanalysis. Chest 2007;131:507516.

    • Search Google Scholar
    • Export Citation
  • 118.

    Kearon C, Ginsberg JS, Julian JA. Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism. JAMA 2006;296:935942.

    • Search Google Scholar
    • Export Citation
  • 119.

    Hospira, Inc. Prescribing information: Heparin sodium injection, USP. 2008. Available at: http://www.hospira.com/Files/heparin_sodium_injection.pdf. Accessed February 1, 2011.

    • Search Google Scholar
    • Export Citation
  • 120.

    Bristol-Myers Squibb. Prescribing information: COUMADIN® TABLETS (Warfarin Sodium Tablets, USP); COUMADIN® FOR INJECTION (Warfarin Sodium for Injection, USP). 2010. Available at: http://packageinserts.bms.com/pi/pi_coumadin.pdf. Accessed February 1, 2011.

    • Search Google Scholar
    • Export Citation
  • 121.

    Glynn RJ, Ridker PM, Goldhaber SZ, Buring JE. Effect of low-dose aspirin on the occurrence of venous thromboembolism: a randomized trial. Ann Intern Med 2007;147:525533.

    • Search Google Scholar
    • Export Citation
  • 122.

    Becattini C, Agnelli G, Poggio R. Aspirin after oral anticoagulants for prevention of recurrence in patients with unprovoked venous thromboembolism. the WARFASA study [abstract]. Blood 2011;118:Abstract 543.

    • Search Google Scholar
    • Export Citation
  • 123.

    Becattini C, Agnelli G, Schenone A. Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med 2012;366:19591967.

  • 124.

    Brighton TA, Eikelboom JW, Mann K. Low-dose aspirin for preventing recurrent venous thromboembolism. N Engl J Med 2012;367:19791987.

  • 125.

    Dennis M, Sandercock PA, Reid J. Effectiveness of thigh-length graduated compression stockings to reduce the risk of deep vein thrombosis after stroke (CLOTS trial 1): a multicentre, randomised controlled trial. Lancet 2009;373:19581965.

    • Search Google Scholar
    • Export Citation
  • 126.

    Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism: the PREPIC (Prevention du Risque d’Embolie Pulmonaire par Interruption Cave) randomized study. Circulation 2005;112:416422.

    • Search Google Scholar
    • Export Citation
  • 127.

    Brender E. Use of emboli-blocking filters increases, but rigorous data are lacking. JAMA 2006;295:989990.

  • 128.

    Stein PD, Kayali F, Olson RE. Twenty-one-year trends in the use of inferior vena cava filters. Arch Intern Med 2004;164:15411545.

  • 129.

    Streiff MB. Vena caval filters: a comprehensive review. Blood 2000;95:36693677.

  • 130.

    Streiff MB. Vena caval filters: a review for intensive care specialists. J Intensive Care Med 2003;18:5979.

  • 131.

    Decousus H, Leizorovicz A, Parent F. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prevention du Risque d’Embolie Pulmonaire par Interruption Cave Study Group. N Engl J Med 1998;338:409415.

    • Search Google Scholar
    • Export Citation
  • 132.

    Elting LS, Escalante CP, Cooksley C. Outcomes and cost of deep venous thrombosis among patients with cancer. Arch Intern Med 2004;164:16531661.

    • Search Google Scholar
    • Export Citation
  • 133.

    Getzen TM, Rectenwald JE. Inferior vena cava filters in the cancer patient: current use and indications. J Natl Compr Canc Netw 2006;4:881888.

    • Search Google Scholar
    • Export Citation
  • 134.

    Millward SF, Grassi CJ, Kinney TB. Reporting standards for inferior vena caval filter placement and patient follow-up: supplement for temporary and retrievable/optional filters. J Vasc Interv Radiol 2005;16:441443.

    • Search Google Scholar
    • Export Citation
  • 135.

    Kim HS, Young MJ, Narayan AK. A comparison of clinical outcomes with retrievable and permanent inferior vena cava filters. J Vasc Interv Radiol 2008;19:393399.

    • Search Google Scholar
    • Export Citation
  • 136.

    Nicholson W, Nicholson WJ, Tolerico P. Prevalence of fracture and fragment embolization of Bard retrievable vena cava filters and clinical implications including cardiac perforation and tamponade. Arch Intern Med 2010;170:18271831.

    • Search Google Scholar
    • Export Citation
  • 137.

    Cervera R, Khamashta MA, Shoenfeld Y. Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis 2009;68:14281432.

    • Search Google Scholar
    • Export Citation
  • 138.

    Lim W, Crowther MA, Eikelboom JW. Management of antiphospholipid antibody syndrome: a systematic review. JAMA 2006;295:10501057.

  • 139.

    Lim W. Antiphospholipid antibody syndrome. Hematology Am Soc Hematol Educ Program 2009:233239.

  • 140.

    Francis CW. Prevention of venous thromboembolism in hospitalized patients with cancer. J Clin Oncol 2009;27:48744880.

  • 141.

    Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double-blind randomized multicentre trial with venographic assessment. ENOXACAN Study Group. Br J Surg 1997;84:10991103.

    • Search Google Scholar
    • Export Citation
  • 142.

    Mismetti P, Laporte S, Darmon JY. Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery. Br J Surg 2001;88:913930.

    • Search Google Scholar
    • Export Citation
  • 143.

    DeBernardo RL, Perkins RB, Littell RD. Low-molecular-weight heparin (dalteparin) in women with gynecologic malignancy. Obstet Gynecol 2005;105:10061011.

    • Search Google Scholar
    • Export Citation
  • 144.

    Akl EA, Terrenato I, Barba M. Low-molecular-weight heparin vs unfractionated heparin for perioperative thromboprophylaxis in patients with cancer: a systematic review and meta-analysis. Arch Intern Med 2008;168:12611269.

    • Search Google Scholar
    • Export Citation
  • 145.

    Couban S, Goodyear M, Burnell M. Randomized placebo-controlled study of low-dose warfarin for the prevention of central venous catheter-associated thrombosis in patients with cancer. J Clin Oncol 2005;23:40634069.

    • Search Google Scholar
    • Export Citation
  • 146.

    Karthaus M, Kretzschmar A, Kroning H. Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial. Ann Oncol 2006;17:289296.

    • Search Google Scholar
    • Export Citation
  • 147.

    Verso M, Agnelli G, Bertoglio S. Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: a double-blind, placebo-controlled, randomized study in cancer patients. J Clin Oncol 2005;23:40574062.

    • Search Google Scholar
    • Export Citation
  • 148.

    Young AM, Billingham LJ, Begum G. Warfarin thromboprophylaxis in cancer patients with central venous catheters (WARP): an open-label randomised trial. Lancet 2009;373:567574.

    • Search Google Scholar
    • Export Citation
  • 149.

    Khorana AA, Dalal M, Tangirala K, Miao R. Higher incidence of venous thromboembolism in the outpatient versus the inpatient setting among U.S. cancer patients [abstract]. Blood 2011;118:Abstract 674.

    • Search Google Scholar
    • Export Citation
  • 150.

    Martino MA, Borges E, Williamson E. Pulmonary embolism after major abdominal surgery in gynecologic oncology. Obstet Gynecol 2006;107:666671.

    • Search Google Scholar
    • Export Citation
  • 151.

    Bergqvist D, Agnelli G, Cohen AT. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med 2002;346:975980.

    • Search Google Scholar
    • Export Citation
  • 152.

    Rasmussen MS, Jorgensen LN, Wille-Jorgensen P. Prolonged prophylaxis with dalteparin to prevent late thromboembolic complications in patients undergoing major abdominal surgery: a multicenter randomized open-label study. J Thromb Haemost 2006;4:23842390.

    • Search Google Scholar
    • Export Citation
  • 153.

    Rana P, Levine MN. Prevention of thrombosis in ambulatory patients with cancer. J Clin Oncol 2009;27:48854888.

  • 154.

    Zangari M, Fink LM, Elice F. Thrombotic events in patients with cancer receiving antiangiogenesis agents. J Clin Oncol 2009;27:48654873.

  • 155.

    Gay F, Hayman SR, Lacy MQ. Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients. Blood 2010;115:13431350.

    • Search Google Scholar
    • Export Citation
  • 156.

    Rajkumar SV, Jacobus S, Callander NS. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 2010;11:2937.

    • Search Google Scholar
    • Export Citation
  • 157.

    Celgene Corporation. Prescribing information: REVLIMID (lenalidomide) capsules. 2010. Available at: http://www.revlimid.com/pdf/REVLIMID_PI.pdf. Accessed February 1, 2011.

    • Search Google Scholar
    • Export Citation
  • 158.

    Celgene Corporation. Prescribing information: THALOMID® (thalidomide) Capsules 50 mg, 100 mg, 150 mg & 200 mg. 2010. Available at: http://www.thalomid.com/pdf/Thalomid%20PI%2072991-10.pdf. Accessed February 1, 2011.

    • Search Google Scholar
    • Export Citation
  • 159.

    Palumbo A, Cavo M, Bringhen S. Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. J Clin Oncol 2011;29:986993.

    • Search Google Scholar
    • Export Citation
  • 160.

    Larocca A, Cavallo F, Bringhen S. Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. Blood 2012;119:933939; quiz 1093.

    • Search Google Scholar
    • Export Citation
  • 161.

    Kearney JC, Rossi S, Glinert K, Henry DH. Venous thromboembolism (VTE) and survival in a cancer chemotherapy outpatient clinic: a retrospective chart review validation of a VTE predictive model [abstract]. Blood 2009;114:Abstract 2503.

    • Search Google Scholar
    • Export Citation
  • 162.

    Price LH, Nguyen MB, Picozzi VJ, Kozarek RA. Portal vein thrombosis in pancreatic cancer: natural history, risk factors, and implications for patient management [abstract]. Presented at the 2010 Gastrointestinal Cancers Symposium; January 22-24, 2010; Orlando, Florida. Abstract 143.

    • Search Google Scholar
    • Export Citation
  • 163.

    Agnelli G, Gussoni G, Bianchini C. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol 2009;10:943949.

    • Search Google Scholar
    • Export Citation
  • 164.

    Riess H, Pelzer U, Opitz B. A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy: final results of the CONKO-004 trial [abstract]. J Clin Oncol 2010;28(Suppl 15):Abstract 4033.

    • Search Google Scholar
    • Export Citation
  • 165.

    Agnelli G, George DJ, Kakkar AK. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med 2012;366:601609.

    • Search Google Scholar
    • Export Citation
  • 166.

    Cohen AT, Nandini B, Wills JO, Ota S. VTE prophylaxis for the medical patient: where do we stand? A focus on cancer patients. Thromb Res 2010;125(Suppl 2):S2129.

    • Search Google Scholar
    • Export Citation
  • 167.

    Clarke-Pearson DL, Synan IS, Dodge R. A randomized trial of low-dose heparin and intermittent pneumatic calf compression for the prevention of deep venous thrombosis after gynecologic oncology surgery. Am J Obstet Gynecol 1993;168:11461153.

    • Search Google Scholar
    • Export Citation
  • 168.

    Ramirez JI, Vassiliu P, Gonzalez-Ruiz C. Sequential compression devices as prophylaxis for venous thromboembolism in high-risk colorectal surgery patients: reconsidering American Society of Colorectal Surgeons parameters. Am Surg 2003;69:941945.

    • Search Google Scholar
    • Export Citation
  • 169.

    Collaboration CT, Dennis M, Sandercock P. Effectiveness of intermittent pneumatic compression in reduction of risk of deep vein thrombosis in patients who have had a stroke (CLOTS 3): a multicentre randomised controlled trial. Lancet 2013;382:516524.

    • Search Google Scholar
    • Export Citation
  • 170.

    Amaragiri SV, Lees TA. Elastic compression stockings for prevention of deep vein thrombosis. Cochrane Database Syst Rev 2000:CD001484.

  • 171.

    Cohen AT, Skinner JA, Warwick D, Brenkel I. The use of graduated compression stockings in association with fondaparinux in surgery of the hip. A multicentre, multinational, randomised, open-label, parallel-group comparative study. J Bone Joint Surg Br 2007;89:887892.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 941 787 205
PDF Downloads 87 55 6
EPUB Downloads 0 0 0